April 21, 2014

McNeil Consumer Healthcare recently introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

April 15, 2014

Greenstone, a generic pharmaceutical subsidiary of Pfizer, announced the introduction of amlodipine besylate/atorvastatin calcium tablets to its roster of products.

April 15, 2014

Mylan announced that it has launched eszopiclone tablets in 1 mg, 2 mg and 3 mg form.

April 15, 2014

Teva Pharmaceutical Industries announced the launch of a generic equivalent to Lunesta (eszopiclone tablets) in 1-,2- and 3-mg form in the United States.

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

April 10, 2014

Lupin announced that it received final approval from the Food and Drug Administration for pioglitazone tablets USP in 15-mg, 30-mg and 45-mg strengths.

April 7, 2014

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration has approved Pradaxa (dabigatran etexilate mesylate), which is used to treat deep venous thrombosis and pulmonary embolism.

April 3, 2014

The Food and Drug Administration on Thursday approved a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose.

April 2, 2014

Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex Ointment.

April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

April 1, 2014

Teva Pharmaceuticals on Tuesday announced the introduction and availability of Raloxifene hydrochloride tablets, USP.

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

March 28, 2014

Pharmacists in New Mexico have become the first in the United States certified to prescribe Narcan (naloxone), which prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension, according to a report published Wednesday by The New Mexican.

March 28, 2014

Sandoz announced the U.S. launch of lansoprazole capsules amoxicillin capsules, USP, and clarithromycin tablets, USP, the generic version of Prevpac.

March 26, 2014

The March/April 2014 Allergy Relief Ingredient Guide breaks down the indication, ingredients, purpose and dosage of Children's Claritin Chewable, Children's Allegra Allergy meltable tablets, Children's Benadryl Allergy Liquid, Nasacort Allergy 24HR, Mucinex Allergy, Hyland's 4 Kids Complete Allergy and Similasan Kids Allergy Eye Relief.

March 25, 2014

The Food and Drug Administration last week approved Amneal Pharmaceuticals' abbreviated new drug application for atovaquone oral suspension USP, 750-mg/5-mL.

March 24, 2014

Upsher-Smith Laboratories on Monday announced that it has entered into a definitive agreement under which New Jersey-based Vertical Pharmaceuticals has acquired Upsher-Smith's rights to Divigel (estradiol gel) 0.1%, Nexa Plus Rx Prenatal Vitamin, and Provella, a probiotic dietary supplement.

March 21, 2014

Pharma Major Lupin announced that Lupin Pharmaceuticals, its U.S. subsidiary, has launched niacin extended-release tablets USP in 500-mg, 750-mg and 1,000-mg strengths.

March 20, 2014

AstraZeneca on Wednesday launched Nexium Direct, a program that provides eligible patients the option of having brand-name Nexium delivered directly to their home.

March 20, 2014

Purdue Pharma recently announced that a Phase 3 study of an investigational extended‐release formulation of hydrocodone bitartrate met its primary efficacy endpoint by showing that patients with chronic low back pain treated with the once‐daily analgesic agent experienced statistically significant reduction in pain compared with placebo.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

March 18, 2014

Pfizer has sued Torrent Pharmaceuticals in an effort to protect its erectile-dysfunction drug Viagra (sildenafil citrate) from generic competition, according to a Bloomberg News report published Tuesday.

March 17, 2014

Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a preventive treatment for deep vein thrombosis, which can lead to pulmonary embolism for patients who have had hip or knee replacement surgery.